scholarly journals Diagnostic value of the lymphocyte-to-monocyte and albumin-to-globulin ratios in patients with colon cancer

2020 ◽  
Author(s):  
Li Huang ◽  
Zhuning Mo ◽  
Zuojian Hu ◽  
Linyan Zhang ◽  
Shanzi Qin ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Clinical Stage ◽  
Diagnostic Value ◽  
Chi Square ◽  
Diagnostic Efficacy ◽  
Ample Evidence ◽  
Lymphocyte To Monocyte Ratio ◽  
Cancer Group ◽  
Healthy Control ◽  
Colon Diseases

Abstract Background: Ample evidence has revealed that the lymphocyte-to-monocyte ratio (LMR) and albumin-to-globulin ratio (AGR) are cancer-related inflammatory markers. The present study aimed to assess whether LMR and AGR, alone or in combination with carcinoembryonic antigen (CEA), was a useful diagnostic marker for colon cancer.Methods: This retrospective study enrolled 251 patients with colon cancer, 171 patients with benign colon diseases, and 187 healthy control subjects from January 2012 to September 2019. Mann-Whitney U test or Chi-square test were used to analyze differences between groups in laboratory parameters and clinicopathological features. The diagnostic value of LMR and AGR combined or not with CEA in colon cancer patients was determined via a receiver operating characteristic (ROC) curve.Results: The levels of LMR and AGR were decreased in the colon cancer group compared with the healthy control and benign colon disease groups. The LMR and AGR were correlated with lymph node metastasis, tumor size, and clinical stage. Moreover, AGR was associated with distant metastasis. Both the LMR (r = −0.137, p = 0.030) and AGR (r = −0.178, p = 0.005) were negatively correlated with the concentration of CEA. LMR or AGR combined with CEA could enhance sensitivity (75.30% for LMR + CEA, 58.57% for AGR + CEA) and generate larger area under curve (AUC; 0.75 for LMR + CEA, 0.74 for AGR + CEA) compared with the LMR (p < 0.001), AGR (p < 0.001), or CEA (p < 0.001) alone.Conclusion: The combination of LMR or AGR with CEA may enhance the sensitivity and diagnostic efficacy of detecting colon cancer from benign colon diseases.

scholarly journals Predictive Values of the Selected Inflammatory Index in the Progression of Colon Cancer Patients

2021 ◽  
Author(s):  
Li Huang ◽  
Zuojian Hu ◽  
Ruixian Luo ◽  
Hailan Li ◽  
Ziji Yang ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Cancer Patients ◽  
Clinical Stage ◽  
Area Under The Curve ◽  
Diagnostic Efficacy ◽  
Ample Evidence ◽  
Predictive Values ◽  
Inflammatory Index ◽  
Healthy Control ◽  
Colon Diseases

Abstract Background: Ample evidence has revealed that the lymphocyte-to-monocyte ratio (LMR), albumin-to-globulin ratio (AGR) and mean platelet volume (MPV) are cancer-related inflammatory markers. The present study aimed to assess a better diagnostic marker for the progression of colon cancer. Methods: This retrospective study enrolled 251 patients with colon cancer, 171 patients with benign colon diseases, and 187 healthy control subjects from January 2012 to September 2020. The receiver operating characteristic (ROC) curve and area under the curve (AUC) were used to determine the diagnostic values of the selected inflammatory index.Results: The levels of LMR, AGR and MPV were decreased in the colon cancer group compared with the healthy control and benign colon disease groups. The LMR, AGR and MPV were all correlated with tumor size. Moreover, LMR and AGR was associated with lymph node metastasis and clinical stage, AGR was related to distant metastasis. Both the LMR (p = 0.030) and AGR (p = 0.005) were negatively correlated with the concentration of carcinoembryonic antigen (CEA). The AUC value of MPV combined with CEA had a good diagnostic ability for distinguishing controls from colon cancer cases (AUC = 0.950) and patients with benign colon diseases (AUC = 0.886). Meanwhile, the combination of LMR or AGR with CEA could enhance the diagnostic efficacy (AUC; 0.746 for LMR + CEA, 0.737 for AGR + CEA) of detecting colon cancer from benign colon diseases. Conclusions: CEA combined with the selected inflammatory index may be used as better blood-based biomarkers in the progression of colon cancer patients.

scholarly journals MiR-106B Represents an Innovative Bio-marker in Cholangiocarcinoma Detection

2020 ◽  
Author(s):  
Ning Wang ◽  
Yanni Li ◽  
Yanfang Zheng ◽  
Huoming Chen ◽  
Xiaolong Wen ◽  
...  
Keyword(s):  
Roc Curve ◽  
Clinical Stage ◽  
Serum Levels ◽  
Diagnostic Value ◽  
Diagnostic Biomarker ◽  
Chi Square ◽  
Chi Square Test ◽  
Healthy Control ◽  
Important Regulator ◽  
Polymerase Chain

Abstract Background Cholangiocarcinoma (CCA) is one of the most aggressive malignancies. Late diagnosis may be responsible for the high mortality. MicroRNA-106b (MiR-106b) is accepted as an important regulator in various human malignancies. The current study was aimed to investigate the diagnostic value of miR-106b in CCA. Methods Serum levels of miR-106b in CCA patients and healthy control were evaluated by quantitative real-time polymerase chain reaction (qRT-PCR). Chi-square test was used to analyze the association of miR-106b with the clinicopathological features. To evaluate the diagnostic value of miR-106b in CCA, the ROC curve was constructed. Results The expression of miR-106b was significantly increased in CCA samples compared with the healthy controls (P < 0.001). The overexpression of miR-106b was remarkable correlated with the lymphatic node metastasis (P = 0.038), clinical stage (P = 0.017) and differentiation (P = 0.009). ROC curve suggested that miR-106b was an effective diagnostic biomarker in CCA with the AUC of 0.913. The optimal cutoff value was 2.525, with the sensitivity of 89.7% and the specificity of 79.3%. Conclusions MiR-106b functions as an oncogene in CCA, which may be an potential diagnostic biomarker for CCA.

The early diagnostic value of combined detection of plasma miR-181b, miR-196a and miR-210 in pancreatic cancer

2019 ◽  
Author(s):  
Gongpan Liu ◽  
Cunhua Shao ◽  
Anyun Li ◽  
Xiaobin Zhang ◽  
Xingjun Guo ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Early Diagnosis ◽  
Operating Characteristic ◽  
Clinical Stage ◽  
Diagnostic Value ◽  
Carbohydrate Antigen ◽  
Healthy Individuals ◽  
Diagnostic Efficacy ◽  
Lymph Nodes Metastasis ◽  
Combined Detection

Abstract Background This study aimed to investigate the effect of combination of plasma miR-181b, miR-196a and miR-210 on early diagnosis of pancreatic cancer (PC).Methods In our study, the plasma was isolated from patients with PC and healthy individuals, respectively. The expressions of miR-181b, miR-196a and miR-210 were detected by qRT-PCR. Moreover, the level of carbohydrate antigen 199 (CA199) was measured by electrochemiluminescence (ECL) assay. Furthermore, the area under the receiver operating characteristic (ROC) curve (AUC) was used to analyze the diagnostic efficacy of miR-181b, miR-196a, miR-210 and CA199, as well as the combination of thses miRNAs in early PC patients and healthy individuals.Results The expressions of miR-181b, miR-196a and miR-210 were significantly upregulated in PC patients. In addition, the level of CA199 was also significantly upregulated in the plasma of PC patients. The expressions of miR-181b, miR-196a and miR-210 were closely associated with lymph nodes metastasis, clinical stage and vascular invasion, but had no correlation with the patient's age, gender and tumor size. Moreover, miR-181b, miR-196a and miR-210 have lower AUC than CA199 in PC patients. The combinations miR-181b + miR-196a, miR-181b + miR-210, miR-196a + miR-210 also have lower AUC than CA199 in PC patients. It is worth noting that the combinations miR-181b + miR-196a + miR-210 have higher AUC than CA199 in PC.Conclusions Our study demonstrated that the combination of plasma miR-181b, miR-196a and miR-210 had good value for PC early diagnosis.

LncRNA CASC2 Plays an Indicative Role in Diagnosing Bladder Cancer

2020 ◽  
Author(s):  
Hao Zi ◽  
Wen-Lin Tao ◽  
Lei Gao ◽  
Zhao-Hua Yu ◽  
Xiao-Dong Bai ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Cancer Patients ◽  
Roc Curve ◽  
Histological Grade ◽  
Diagnostic Value ◽  
Expression Level ◽  
Chi Square ◽  
Healthy Group ◽  
Cancer Group ◽  
Incidence And Mortality

Abstract Background: Bladder cancer is a common cancer of urinary system, with high incidence and mortality. LncRNA CASC2 as a tumor suppressor has been reported to be involved in many human tumors. In this study, we aimed to explore the diagnostic value of CASC2 for bladder cancer patients.Methods: qRT-PCR was used to detect the expression level of CASC2 in 140 bladder cancer patients and 90 healthy volunteers. The differences of CASC2 expression between the cancer group and healthy group were analyzed using student’s t test. The correlation of CASC2 expression with clinical characteristics of the bladder cancer patients was estimated with Chi-square test. In addition, ROC curve was plotted to evaluate the diagnostic value of CASC2 for bladder cancer patients.Results: Serum CASC2 level was lower in bladder cancer patients than that in healthy group (P<0.05). The expression level of CASC2 was significantly associated with histological grade (P=0.000), TNM stage (P=0.000), and lymph node metastasis (P=0.001). The area under the ROC curve (AUC) was 0.864 and the optimal cutoff value was 0.955, suggesting the diagnostic value of CASC2 for bladder cancer. The diagnostic sensitivity was 77.8% and specificity was 85.7%.Conclusion: CASC2 may be a novel biomarker for early diagnosis of bladder cancer.

scholarly journals Lack of Efficacy of Combined Carbohydrate Antigen Markers for Lung Cancer Diagnosis

2020 ◽  
Vol 2020 ◽  
pp. 1-10
Author(s):  
Zhineng Wen ◽  
Ying Huang ◽  
Zhougui Ling ◽  
Jifei Chen ◽  
Xiaomou Wei ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Tumor Markers ◽  
Cell Lung Cancer ◽  
Area Under The Curve ◽  
Nonsmall Cell Lung Cancer ◽  
Diagnostic Value ◽  
Carbohydrate Antigen ◽  
Ca 125 ◽  
Chi Square ◽  
Diagnostic Efficacy

Background. Lung cancer (LC) is top-ranked in cancer incidence and is the leading cause of cancer death globally. Combining serum biomarkers can improve the accuracy of LC diagnosis. The identification of the best potential combination of traditional tumor markers is essential for LC diagnosis. Patients and Methods. Blood samples were collected from 132 LC cases and 118 benign lung disease (BLD) controls. The expression levels of ten serum tumor markers (CYFR21, CEA, NSE, SCC, CA15-3, CA 19-9, CA 125, CA50, CA242, and CA724) were assayed, and that the expression in the levels of tumor markers were evaluated, isolated, and combined in different patients. The performance of the biomarkers was analyzed by receiver operating characteristic (ROC) analyses, and the difference between combinations of biomarkers was compared by Chi-square ( χ 2 ) tests. Results. As single markers, CYFR21 and CEA showed good diagnostic efficacy for nonsmall cell lung cancer (NSCLC) patients, while NSE and CEA were the most sensitive in the diagnosis of small cell lung cancer (SCLC). The area under the curve (AUC) value was 0.854 for the panel of four biomarkers (CYFR21, CEA, NSE, and SCC), 0.875 for the panel of six biomarkers (CYFR21, CEA, NSE, SCC, CA125, and CA15-3), and 0.884 for the panel of ten markers (CYFR21, CEA, NSE, SCC, CA125, CA15-3, CA19-9, CA50, CA242, and CA724). With a higher sensitivity and negative predictive value (NPV), the diagnostic accuracy of the three panels was better than that of any single biomarker, but there were no statistically significant differences among them (all P values > 0.05). However, the panel of six carbohydrate antigen (CA) biomarkers (CA125, CA15-3, CA19-9, CA50, CA242, and CA724) showed a lower diagnostic value (AUC: 0.776, sensitivity: 59.8%, specificity: 73.0%, and NPV: 60.4%) than the three panels ( P value < 0.05). The performance was similar even when analyzed individually by LC subtypes. Conclusion. The biomarkers isolated are elevated for different types of lung cancer, and the panel of CYFR21, CEA, NSE, and SCC seems to be a promising serum biomarker for the diagnosis of lung cancer, while the combination with carbohydrate antigen markers does not improve the diagnostic efficacy.

scholarly journals Diagnostic Value of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Crohn’s Disease

2017 ◽  
Vol 2017 ◽  
pp. 1-5 ◽  
Author(s):  
Jue-Rong Feng ◽  
Xiao Qiu ◽  
Fan Wang ◽  
Peng-Fei Chen ◽  
Qian Gao ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Low Cost ◽  
Diagnostic Value ◽  
Neutrophil To Lymphocyte Ratio ◽  
Platelet To Lymphocyte Ratio ◽  
Diagnostic Efficacy ◽  
Lymphocyte Ratio ◽  
Lymphocyte To Monocyte Ratio ◽  
Complete Blood Counts

The aim of this study is to investigate the diagnostic efficacy of neutrophil-to-lymphocyte ratio (NLR), neutrophil-to-monocyte ratio (NMR), lymphocyte-to-monocyte ratio (LMR), and platelet-to-lymphocyte ratio (PLR) in patients with Crohn’s disease (CD) and non-CD controls. These ratios were all derived from complete blood counts. Two hundred and six participants including CD inpatients and non-CD controls were retrospectively enrolled. We found statistically higher NLR and PLR and lower LMR in CD patients than in non-CD controls (all P<0.01). However, NMR was not different between the two groups (P=0.18). In addition, NLR, PLR, and LMR were associated with CRP and ESR. Optimal cutoffs for NLR and PLR were 2.72 (sensitivity: 68.3%, specificity: 75.9%, and overall accuracy: 70.1%) and 132.88 (sensitivity: 76.7%, specificity: 84.8%, and overall accuracy: 80.8%), respectively. In conclusion, the NLR and PLR might be effective, readily available, and low-cost biomarkers for differentiating CD patients from non-CD controls.

Diagnostic Value of Computed Tomography in the Colon Cancer: In Terms of the Staging System

1989 ◽  
Vol 25 (1) ◽  
pp. 52
Author(s):  
J M Lee ◽  
J H Moon ◽  
D J Lee ◽  
C S Choi ◽  
I W Kang ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Colon Cancer ◽  
Staging System ◽  
Diagnostic Value

scholarly journals Diagnostic Value of C-Reactive Protein in Discrimination between Uncomplicated and Complicated Parapneumonic Effusion

Diagnostics ◽  
2020 ◽  
Vol 10 (10) ◽  
pp. 829
Author(s):  
Yana Kogan ◽  
Edmond Sabo ◽  
Majed Odeh
Keyword(s):  
Area Under The Curve ◽  
Diagnostic Value ◽  
Parapneumonic Effusion ◽  
C Reactive Protein ◽  
Diagnostic Efficacy ◽  
Reactive Protein ◽  
Significant Difference ◽  
Study Population ◽  
Complicated Parapneumonic Effusion

Objectives: The role of serum C-reactive protein (CRPs) and pleural fluid CRP (CRPpf) in discriminating uncomplicated parapneumonic effusion (UCPPE) from complicated parapneumonic effusion (CPPE) is yet to be validated since most of the previous studies were on small cohorts and with variable results. The role of CRPs and CRPpf gradient (CRPg) and of their ratio (CRPr) in this discrimination has not been previously reported. The study aims to assess the diagnostic efficacy of CRPs, CRPpf, CRPr, and CRPg in discriminating UCPPE from CPPE in a relatively large cohort. Methods: The study population included 146 patients with PPE, 86 with UCPPE and 60 with CPPE. Levels of CRPs and CRPpf were measured, and the CRPg and CRPr were calculated. The values are presented as mean ± SD. Results: Mean levels of CRPs, CRPpf, CRPg, and CRPr of the UCPPE group were 145.3 ± 67.6 mg/L, 58.5 ± 38.5 mg/L, 86.8 ± 37.3 mg/L, and 0.39 ± 0.11, respectively, and for the CPPE group were 302.2 ± 75.6 mg/L, 112 ± 65 mg/L, 188.3 ± 62.3 mg/L, and 0.36 ± 0.19, respectively. Levels of CRPs, CRPpf, and CRPg were significantly higher in the CPPE than in the UCPPE group (p < 0.0001). No significant difference was found between the two groups for levels of CRPr (p = 0.26). The best cut-off value calculated by the receiver operating characteristic (ROC) analysis for discriminating UCPPE from CPPE was for CRPs, 211.5 mg/L with area under the curve (AUC) = 94% and p < 0.0001, for CRPpf, 90.5 mg/L with AUC = 76.3% and p < 0.0001, and for CRPg, 142 mg/L with AUC = 91% and p < 0.0001. Conclusions: CRPs, CRPpf, and CRPg are strong markers for discrimination between UCPPE and CPPE, while CRPr has no role in this discrimination.

scholarly journals Evaluation of Diagnostic Value in Using a Panel of Multiple Tumor-Associated Antigens for Immunodiagnosis of Cancer

2014 ◽  
Vol 2014 ◽  
pp. 1-7 ◽  
Author(s):  
Peng Wang ◽  
Chunhua Song ◽  
Weihong Xie ◽  
Hua Ye ◽  
Kaijuan Wang ◽  
...  
Keyword(s):  
Negative Likelihood Ratio ◽  
Cyclin B1 ◽  
Diagnostic Value ◽  
Antibody Detection ◽  
Enzyme Linked Immunosorbent Assay ◽  
Predictive Values ◽  
Multiple Tumor ◽  
Tumor Associated Antigens ◽  
Cancer Group ◽  
Kappa Value

To determine whether a panel of multiple tumor-associated antigens (TAAs) would enhance antibody detection, the diagnostic value of autoantibodies to a panel of multiple TAAs in cancer has been evaluated. The TAAs used in this study was composed of eight TAAs including Imp1, p62, Koc, p53, C-myc, Cyclin B1, Survivin, and p16 full-length recombinant proteins. Enzyme-linked immunosorbent assay and immunoblotting were used to detect antibodies in 304 cancer sera and also 58 sera from normal individuals. The antibody frequency to any individual TAA in cancer was variable but rarely exceeded 20%. With the successive addition of TAAs to a final combination of total of eight antigens, there was a stepwise increase of positive antibody reactions reaching a sensitivity of 63.5% and a specificity of 86.2% in the combined cancer group. In different types of cancer, the ranges of positive and negative likelihood ratio were 4.07–4.76 and 0.39–0.51, respectively, and the ranges of positive and negative predictive values were 74.2–88.7% and 58.8–75.8%, respectively. Agreement rate and Kappa value were 67.1% and 0.51, respectively. These results further support our previous hypothesis that detection of anti-TAAs autoantibodies for diagnosis of certain type of cancer can be enhanced by using a miniarray of several TAAs.

Sign in / Sign up

Export Citation Format

Share Document